鼠疫桿菌診斷市場規模、佔有率、成長分析，按產品、按診斷測試、按技術、按最終用戶、按地區 - 產業預測 2025-2032

2023 年全球鼠疫桿菌診斷市場規模價值為 34.7 億美元，預計將從 2024 年的 36.2 億美元成長到 2032 年的 50.3 億美元，預測期內（2025-2032 年）的複合年成長率為 4.2%。

預計全球鼠疫桿菌菌診斷市場將以顯著的速度成長，這得益於鼠疫桿菌感染疾病盛行率的上升、診斷工具技術的進步以及公眾對早期檢測重要性的認知的提高。分子診斷技術的日益普及也是推動市場擴張的關鍵因素。此外，全球食源性疾病的爆發和鼠疫桿菌病病例的增加也加劇了市場需求。然而，診斷製造商之間的競爭加劇、政府對醫療保健的資金不足以及組織的批量採購等挑戰可能會阻礙成長。北美、歐洲和亞太地區是影響市場的關鍵地區，在政府措施、加強醫療保健基礎設施和開發創新診斷檢測等的支持下，確保了未來幾年的強勁成長。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 技術進步

鼠疫桿菌診斷市場規模（依產品分類）

• 市場概況
• 裝置
• 套件和試劑

鼠疫桿菌診斷市場規模（依診斷測試）

• 市場概況
• 糞便培養
• 影像檢查
• 血清學檢測
• 大腸鏡檢查
• ELISA
• 免疫檢測
• 管凝集反應
• 電腦斷層掃描
• 超音波
• 大腸鏡檢查
• 其他

鼠疫桿菌診斷市場規模（依技術分類）

• 市場概況
• 免疫檢測
• DNA 探針
• 聚合酵素鏈鎖反應（PCR）
• 流式細胞技術
• 層析法
• 其他

鼠疫桿菌診斷市場規模（按最終用戶分類）

• 市場概況
• 醫院
• 公共衛生研究所
• 商業研究院
• 其他

鼠疫桿菌菌診斷市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Abbott Laboratories（USA）
• Thermo Fisher Scientific（USA）
• Bio-Rad Laboratories（USA）
• Hologic, Inc.（USA）
• Becton, Dickinson and Company（BD）（USA）
• Danaher Corporation（USA）
• PerkinElmer, Inc.（USA）
• QIAGEN NV（Netherlands）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Siemens Healthineers AG（Germany）
• bioMerieux SA（France）
• Merck KGaA（Germany）
• Lonza Group AG（Switzerland）
• Agilent Technologies, Inc.（USA）
• Illumina, Inc.（USA）
• bioAffinity Technologies, Inc.（USA）
• Gen-Probe Incorporated（USA）

結論和建議

Global Yersinia Diagnostics Market size was valued at USD 3.47 billion in 2023 and is poised to grow from USD 3.62 billion in 2024 to USD 5.03 billion by 2032, growing at a CAGR of 4.2% during the forecast period (2025-2032).

The global Yersinia diagnostics market is expected to experience significant growth driven by the rising incidence of Yersinia infections, technological advancements in diagnostic tools, and heightened public awareness regarding the importance of early detection. The increasing adoption of molecular diagnostic technologies is a crucial factor propelling market expansion. Additionally, the prevalence of food-borne diseases and a rise in yersiniosis cases globally are contributing to market demand. However, challenges such as intensified competition among diagnostic producers, inadequate government funding for healthcare, and bulk procurement by organizations may hinder growth. North America, Europe, and Asia Pacific are key regions influencing the market, supported by governmental initiatives, enhanced healthcare infrastructure, and the creation of innovative diagnostic assays, ensuring robust growth in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Yersinia Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Yersinia Diagnostics Market Segmental Analysis

Global Yersinia Diagnostics Market is segmented by Product, Diagnostic Test, Technology, End User and region. Based on Product, the market is segmented into Instruments and Kits and Reagents. Based on Diagnostic Test, the market is segmented into Stool Culture, Imaging Tests, Serological Tests, Colonoscopy, ELISA, Radioimmunoassay, Tube Agglutination, CT Scan, Ultrasonography, Colonoscopy and Others. Based on Technology, the market is segmented into Immunoassay, DNA Probes, Polymerase Chain Reaction (PCR), Flow Cytometry, Chromatography and Others. Based on End User, the market is segmented into Hospitals, Public Health Laboratories, Commercial Laboratories and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Yersinia Diagnostics Market

The global demand for Yersinia diagnostics is primarily driven by the increasing prevalence of Yersinia infections, particularly those caused by Yersinia enterocolitica and Yersinia pseudotuberculosis, which are notable contributors to foodborne illnesses and gastrointestinal disorders worldwide. The incidence rates of these infections fluctuate across different regions and over time; however, areas experiencing higher occurrences are generating significant needs for diagnostic solutions. Consequently, healthcare professionals and public health organizations are actively seeking reliable diagnostic tools to accurately detect and manage Yersinia infections, particularly as case numbers continue to rise, thereby fueling market growth in this sector.

Restraints in the Global Yersinia Diagnostics Market

The global Yersinia diagnostics market faces significant challenges due to the intricate nature of Yersinia infections. These infections can present a variety of nonspecific symptoms, such as diarrhea, abdominal pain, and fever, which overlap with those of other gastrointestinal disorders. This ambiguity complicates clinical diagnosis and can lead to misinterpretations, especially as Yersinia infections may also mimic conditions like appendicitis. Such difficulties in accurately and promptly identifying Yersinia infections can reduce the demand for diagnostic tests, thereby restraining market growth. Consequently, the complexity and nonspecific nature of these infections pose obstacles to effective diagnosis and treatment.

Market Trends of the Global Yersinia Diagnostics Market

The Global Yersinia Diagnostics market is experiencing a significant shift towards molecular diagnostic methods, marking a key trend in the industry. The adoption of advanced technologies like polymerase chain reaction (PCR) assays and nucleic acid amplification tests (NAATs) is on the rise, primarily due to their superior sensitivity, specificity, and reduced turnaround times compared to traditional culture-based techniques. These molecular methods enable the rapid and accurate detection of Yersinia DNA in clinical specimens, enhancing diagnostic capabilities. Consequently, healthcare providers and laboratories are increasingly investing in these advanced platforms, propelling the growth of the Yersinia diagnostics market as they strive for quicker and more reliable pathogen identification.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement

Global Yersinia Diagnostics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Instruments
• Kits and Reagents

Global Yersinia Diagnostics Market Size by Diagnostic Test & CAGR (2025-2032)

• Market Overview
• Stool Culture
• Imaging Tests
• Serological Tests
• Colonoscopy
• ELISA
• Radioimmunoassay
• Tube Agglutination
• CT Scan
• Ultrasonography
• Colonoscopy
• Others

Global Yersinia Diagnostics Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Immunoassay
• DNA Probes
• Polymerase Chain Reaction (PCR)
• Flow Cytometry
• Chromatography
• Others

Global Yersinia Diagnostics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Public Health Laboratories
• Commercial Laboratories
• Others

Global Yersinia Diagnostics Market Size & CAGR (2025-2032)

• North America (Product, Diagnostic Test, Technology, End User)
  • US
  • Canada
• Europe (Product, Diagnostic Test, Technology, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Diagnostic Test, Technology, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Diagnostic Test, Technology, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Diagnostic Test, Technology, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioAffinity Technologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gen-Probe Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations